跳到正文
原文
Endpoints News 生物医药· Max Gelman·· 2 小时前AI 评分55

默沙东的抗体药物偶联物在胃癌 III 期研究中成功

Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer

AI 导读

默沙东的抗体药物偶联物在胃癌 III 期研究中成功,可能缓解 Keytruda 的专利悬崖压力。

正文

An ex­per­i­men­tal an­ti­body-drug con­ju­gate from Mer­ck has suc­ceed­ed in an­oth­er Phase 3 can­cer study, po­ten­tial­ly help­ing off­set Keytru­da’s loom­ing patent cliff.

Mer­ck

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news